Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 48.8% in December

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 32,200 shares, a decline of 48.8% from the December 15th total of 62,900 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 209,700 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets cut their price target on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, December 16th.

Alzamend Neuro Trading Up 3.5 %

Shares of NASDAQ ALZN opened at $1.17 on Thursday. The firm’s fifty day moving average is $1.26 and its two-hundred day moving average is $2.10. Alzamend Neuro has a 52-week low of $1.06 and a 52-week high of $15.06.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.